Related Experiment Video
Updated: May 10, 2025
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
Oxaliplatin-induced diffuse alveolar hemorrhage: A case report
Toshiaki Tsurui1, Emiko Mura2, Atsushi Horiike2
1Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo 1428555, Tōkyō, Japan. t.tsurui@med.showa-u.ac.jp.
World Journal of Clinical Oncology
|April 28, 2025
Summary
Prompt diagnosis of diffuse alveolar hemorrhage (DAH) is crucial for patients on oxaliplatin chemotherapy. Early bronchoscopy and treatment improve outcomes in acute respiratory failure.
Area of Science:
- Oncology
- Pulmonology
- Toxicology
Background:
- Drug-induced lung injury is a significant adverse effect of chemotherapy.
- Diffuse alveolar hemorrhage (DAH) is a life-threatening complication of drug-induced lung injury.
- Nonspecific clinical signs make DAH diagnosis challenging, necessitating bronchoscopy.
Observation:
- A patient receiving fluoropyrimidine and oxaliplatin for esophageal cancer developed fever and cough.
- Chest imaging showed diffuse ground-glass opacities, prompting bronchoscopy.
- Bronchoalveolar lavage confirmed DAH, despite initial rapid respiratory deterioration.
Findings:
- High-dose corticosteroid therapy and respiratory support were initiated.
- The patient's condition improved, leading to successful extubation.
- This case highlights the importance of timely DAH diagnosis in chemotherapy patients.
Implications:
- Early diagnosis and intervention are critical for managing DAH in patients undergoing chemotherapy.
- Bronchoscopy is essential for confirming DAH in patients with acute respiratory failure.
- Optimizing treatment strategies can improve survival rates for DAH patients.
